Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,492 across all filing types
Latest filing 2016-11-01 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory filing reporting monthly share capital movements rather than a full financial report or announcement of a report. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2016-11-01 English
JOINT ANNOUNCEMENT - GRANTING OF WAIVER UNDER RULE 14.41(a) OF THE LISTING RULES
Regulatory Filings Classification · 95% confidence The document is a joint announcement by Lippo Limited and Hongkong Chinese Limited regarding the granting of a waiver under Rule 14.41(a) of the Listing Rules. It references a previous announcement about a major transaction and discusses the timing for despatching circulars to shareholders. The document is short (3641 characters) and primarily serves as a regulatory announcement about compliance with listing rules and timing for shareholder circulars. It does not contain financial statements, detailed financial data, or the actual circulars themselves. It is an announcement related to regulatory compliance and procedural matters rather than a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-10-31 English
DISCLOSURE PURSUANT TO RULE 13.14 OF THE LISTING RULES - ADVANCE TO AN ENTITY
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to Rules 13.14 and 13.15 of the Hong Kong Listing Rules, disclosing details of advances made to an entity (LAAPL Subsidiary). It references previous announcements and provides updated financial information about loans and advances. The content is regulatory in nature, related to compliance with listing rules, and does not constitute a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive disclosure rather than just announcing a report's release. The document fits best under Regulatory Filings (RNS) as it is a compliance disclosure under listing rules without being a formal financial report or other specific filing type.
2016-10-20 English
JOINT ANNOUNCEMENT - MAJOR TRANSACTION AND AMENDMENT OF TERMS OF PREVIOUS TRANSACTIONS
Capital/Financing Update Classification · 95% confidence The document is a joint announcement by Lippo Limited and Hongkong Chinese Limited regarding a major transaction involving a loan facility (the October 2016 Loan Facility) and amendments to previous loan transactions. It references compliance with the Hong Kong Listing Rules, specifically Chapter 14 which governs major transactions requiring reporting, announcement, and shareholders' approval. The document details the terms of the loan agreement, the parties involved, the percentage ratios triggering the major transaction classification, and the procedural steps including written shareholder approvals and the forthcoming circular to shareholders. The text is an announcement of a major transaction and related amendments, not a full financial report or detailed management discussion. It does not contain financial statements or earnings data but focuses on the transaction details and regulatory compliance. Therefore, the document fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2016-10-20 English
DISCLOSEABLE TRANSACTION - EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA IN RESPECT OF BYETTA AND BYDUREON
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a discloseable transaction involving an exclusive license agreement between 3SBIO Inc. and AstraZeneca. It details the terms of the license, payments, and strategic implications. The text references compliance with listing rules and percentage ratios for discloseable transactions, indicating it is a regulatory announcement about a material transaction. There are no financial statements or detailed financial performance data presented, nor is this a transcript, management report, or earnings release. The document is lengthy (15,000 characters) and contains detailed transaction information, which fits the profile of a Capital/Financing Update (CAP) as it relates to a significant licensing deal and associated payments. It is not a report publication announcement or a regulatory filing fallback because it contains substantive transaction details rather than just a notice or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-10-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorised and issued share capital for the month ended 30/09/2016. It includes tables showing share balances, movements, share options, warrants, convertibles, and other share issuance or repurchase activities. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly changes in share capital and securities. It is not a financial report, earnings release, or management discussion, but a formal regulatory filing about share capital movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. The document length is substantial and contains detailed data, not just an announcement of a report. Therefore, the correct classification is SHA with high confidence.
2016-10-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.